Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

d will do what is in its control to accomplish that goal. The Board cannot, however, act without due consideration of the rights of third party lenders or the resulting financial impact on the company of such actions.

In closing, I want to emphasize again that the focus of Amylin at this crucial time is on executing our business strategy and having the right management team and Board to lead the company and create maximum value for all shareholders. We look forward to continued constructive dialogue with our shareholders and opportunities to discuss our strong slate of nominees, who we believe will best serve the interests of all shareholders, and further outline the company's strategy in the coming weeks.

    Very truly yours,

    James N. Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA, SYMLIN and/or exenatide once weekly and the revenues generated from BYETTA and SYMLIN may be affected by competition; unexpected new data; safety
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
(Date:3/3/2015)... LITTLE FALLS, N.J. , March 3, 2015 /PRNewswire/ ... a biotechnology company specializing in the development of and ... of damaged tissues and organs, announced today that it ... Purchase Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin ... required under the Agreement, Amarantus made the final payments ...
(Date:3/3/2015)... 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... journal, Expert Opinion on Biological Therapy , Dr. ... Zhenggang Zhang , at the Henry Ford Hospital in ... beta 4 (TB4) has the capacity to promote CNS ... more post-injury, leading to neurological recovery in each case.  ...
(Date:3/3/2015)... 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... the lives of pets, announced today that it will release ... 12, 2015 after the market close. The Company will host ... Interested parties may access the call by ... internationally, and using conference ID 98449349.  The ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... May 26 , - Production Increase Brings ... Therapeutics (Euronext: AMT), a leader in the field,of ... a Cooperative,Research and Development Agreement from the National ... Institutes of Health (NIH), Bethesda,Maryland, that promises to ...
... AMLN ) will Web cast its Annual Meeting ... PT from the company,s corporate,headquarters in San Diego, CA. ... Executive Officer of Amylin Pharmaceuticals,will be providing a corporate ... and a recording will be made,available following the event. ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... Patent 2,360,833 entitled "Reovirus for the Treatment ... use of one or more,recombinant reoviruses to ... provides the Company with additional patent protection ...
Cached Biology Technology:AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 3Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent 2
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... for months after a traumatic brain injury (TBI), revealing ... new research led by the University of Melbourne, Australia ... Neurotrauma Initiative is published in the latest issue of ... Around 400,000 Australians have a disability related to traumatic ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... results on Wednesday, November 10, 2010 after the markets close. PDL,s ... Eastern Time to discuss the financial results.   ... call via phone, please dial (866) 271-5140 from the United States ...
... HAGUE (2 November 2010)A unique acacia known as a "fertilizer ... maize yields in smallholder agriculture in Zambia and Malawi, according ... The findings were central to the arguments of agroforestry experts ... technology more widely throughout the African nations most vulnerable to ...
Cached Biology News:Study provides treatment hope for long term effects of brain trauma 2PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010 2Scientists find that evergreen agriculture boosts crop yields 2Scientists find that evergreen agriculture boosts crop yields 3
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
... 1 ( Abpromise for all tested ... peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF GDVKFVCVGG ... acids 1-99 of Human Uridine Phosphorylase 1 ... 7378 Swiss Protein ID: ...
Nucleobindin 1 [NUCB1]...
Biology Products: